ClinConnect ClinConnect Logo
Search / Trial NCT07014891

fNIRS-Driven Visual Feedback Training to Restore Walking After Stroke

Launched by SHENGJING HOSPITAL · Jun 10, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Stroke Visual Feedback Functional Near Infrared Spectroscopy Walking Ability

ClinConnect Summary

This clinical trial is studying a new way to help stroke patients improve their walking ability through a special training program. After a stroke, many people experience weakness on one side of their body, which can make walking difficult. The researchers will test a system called MRS-FS that uses real-time visual feedback to help patients safely practice movement and strengthen their legs while lying down. This method aims to make rehabilitation more engaging and effective, compared to traditional training, which can sometimes feel overwhelming and frustrating.

To be eligible for the study, participants must be between 18 and 75 years old and have experienced their first stroke within the last six months, causing weakness in one leg. They should be stable and able to participate in physical activity. The trial will last four weeks, during which participants will be divided into two groups: one will use the MRS-FS system, while the other will participate in a more traditional training method using a ball. Assessments will be conducted before and after the training to measure improvements in walking and brain function. This study aims to find out if the new training method can help stroke survivors walk better and regain their independence.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1: Vital signs are stable, with no severe cardiopulmonary diseases, making the patient suitable for exercise testing.
  • 2: All patients are diagnosed with stroke by head CT or MRI, with clinical manifestations of unilateral limb hemiplegia.
  • 3: The Brunnstrom stage of the lower limb is 3-5, quadriceps muscle strength is ≥ grade 3, modified Ashworth scale for the lower limb is \< grade 2, and Hoffer walking scale is ≥ grade 2.
  • 4: This is their first onset of the disease, with a disease course of ≤ 6 months, and the condition is stable.
  • 5: Patients have no severe cognitive impairment or sensory aphasia, can understand and actively participate in the training program, and have provided informed consent by signing the consent form for this clinical study.
  • 6: Age: 18-75 years old, no gender restrictions.
  • Exclusion Criteria:
  • 1: Patients with tumors, tuberculosis, hematological diseases, or functional impairments of vital organs such as the heart or liver.
  • 2: Those with lower limb musculoskeletal disorders, such as knee arthritis or lower limb fractures.
  • 3: Individuals with severe abnormal muscle tone in the limbs or joint contracture deformities.
  • 4: Patients experiencing severe pain that prevents them from tolerating physical activity.
  • 5: Special populations, such as individuals with mental illnesses, breastfeeding women, or pregnant women.

About Shengjing Hospital

Shengjing Hospital, affiliated with the China Medical University, is a leading medical institution dedicated to advancing healthcare through innovative clinical research and trials. With a strong emphasis on multidisciplinary collaboration, the hospital leverages its state-of-the-art facilities and a team of experienced healthcare professionals to conduct comprehensive studies aimed at improving patient outcomes. Shengjing Hospital is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring that all clinical trials are designed to enhance medical knowledge and provide safe, effective treatment options for diverse patient populations.

Locations

Shenyang, Liaoning, China

Patients applied

0 patients applied

Trial Officials

Xue Jiang

Study Chair

Shengjing Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported